Slides
Page 2
3Q25 | Earnings Presentation
Page 3
Disclaimer This is a brief presentation of the main highlights of the quarterly information of Hospital Mater Dei SA (“Mater Dei” or “Company”) for the quarter and year ended on September 30, 2025 (“Financial Statements”). This presentation has been summarized and is not intended to be complete. The Company's shareholders and potential investors must always read this presentation together with the Quarterly Information published in the IR and CVM website. This presentation was prepared for informational purposes only and should not be taken as a request for an offer to buy or sell any securities and should not be treated as an investment recommendation. No statement, express or otherwise, is made regarding the accuracy, certainty or comprehensiveness of the information contained in this presentation. The Company's past performance is not an indicative of future results. This presentation should not be used as the basis for any agreement or contract. Information regarding the Mater Dei Hospital, its activities, economic and financial position and the risks inherent to its activities, as well as its financial statements, can be found on the world wide web, on the Mater Dei website (https://ri.materdei.com.br/en).
Page 4
HUB RMBH Mater Dei Santo Agostinho Belo Horizonte/MG Mater Dei Contorno Belo Horizonte/MG HUB BAHIA Mater Dei Salvador Salvador/BA Mater Dei Emec Feira de Santana/BA HUB BRASIL CENTRAL Mater Dei Goiânia Goiânia/GO Mater Dei Santa Clara Uberlândia/MG Mater Dei Santa Genoveva Uberlândia/MG Mater Dei CDI Uberlândia/MG Mater Dei Betim-Contagem Betim/MG Mater Dei Nova Lima Nova Lima/MG SÃO PAULO Mater Dei São Paulo [em construção]
Page 5
HIGHLIGHTS CEO COMMENTS Operacional e financial highlights of units ✓ All time high numbers and indicators ✓ Award received in the CONAHP program after validation of indicators. ✓ Highest quarterly NPS in the 3Q25 and highest monthly NPS in October 2025. Awards and Hospital Quality Indicators ✓ New Robot at the Nova Lima unit. ✓ New Robotfor orthopedic surgery at the Uberlândia unit. ✓ In Salvador, the first robotic-assisted cardiac surgery performed in the North and Northeast regions of Brazil. Robotic-Assisted Surgery Highlights ✓ A revolution in onco-hematological treatment. ✓ Personalized immunotherapy based on genetic modification of T lymphocytes. CAR-T Cell Therapy At the Contorno Unit
Page 6
83.436 78.350 77.813 87.369 87.473 6.572 6.988 7.201 6.980 7.289 3T24 4T24 1T25 2T25 3T25 Nº de Paciente-dia Ticket Médio (R$) Operational Highlights Average operational beds and occupancy rate Number of paciente-day and average ticket (BRL) 1.251 1.187 1.166 1.231 1.246 72,5% 71,7% 74,2% 78,0% 76,3% 77,0% 77,0% 79,7% 83,0% 81,7% 3Q24 4Q24 1Q25 2Q25 3Q25 Operational Beds Occupancy Rate Occupancy rate (+patient day hospital)
Page 7
488 487 499 546 568 3Q24 4Q24 1Q25 2Q25 3Q25 2,41 2,56 2,64 2,55 2,67 3Q24 4Q24 1Q25 2Q25 3Q25 Average Ticket – BRL million / Occupied Bed Net Revenue – BRL million -3% +11% Revenue + 9% +12%
Page 8
78 78 74 77 73 15,9% 16,1% 14,9% 14,1% 12,9% 3Q24 4Q24 1Q25 2Q25 3Q25 348 358 356 381 397 71,3% 73,5% 71,2% 69,8% 69,9% 3Q24 4Q24 1Q25 2Q25 3Q25 Costs of services provided – BRL million % net revenue -1.4pp Adjusted Net Operational Expenses – BRL million % net revenue -0.8pp Costs and Expenses
Page 9
91 78 97 115 126 18,6% 15,9% 19,3% 21,1% 22,2% 3Q24 4Q24 1Q25 2Q25 3Q25 EBITDA and EBITDA Margin – BRL Million +1.8pp % adjusted margin EBITDA Adjusted EBITDA Note: 2024 figures are adjusted for the disposal of assets related to the CSN divestment, for Nova Lima's pre-operational expenses, and for the reversal of contingencies.
Page 10
Adjusted Net Profit and Net Margin - BRL Million DSO, DPO and DIO¹ - days +1.0pp Net Profit and Working Capital 124 130 110 110 110 114 117 115 50 43 40 46 50 46 49 48 49 46 35 42 39 38 1Q24 2Q24 3Q24 4Q24 1Q25 2Q25 3Q25 DSO DSO ex-HPD DPO DIO 1. Days sales outstanding (DSO) calculated as Accounts Receivable / (Gross Revenue LTM/365); days payables outstanding (DPO) calculated as (Suppliers - Goods of a permanent nature) / (Costs and Expenses - Personnel and Depreciation LTM/365) ;and days of inventory outstanding (DIO) calculated as average Inventories/ (Materials and Medicines LTM/365). % Adjusted Net Margin % Net Margin 25 8 27 15 16 7 40 25 20 27 35 8,2% 5,1% 5,0% 6,1% 5,1% 1,7% 4,1% 4,8% 3Q24 4Q24 1Q25 2Q25 3Q25 Net Income Deferred Income Tax or Exchange Expanses
Page 11
1,3 1,6 1,8 Net Debt/EBITDA (LTM) Net debt/ EBITDA x xx Cash Flow and Leverage Total Debt Cash Flow- BRL Million (Consolidated) 756 638 680 710 772 738 1.466 1.410 1.417 3Q24 2Q25 3Q25 Cash and cash equivalent Net debt Total debt 1. According to the covenant of the 1st debenture issue of the Company: considering the sum of the balances of loans, financi ng and debentures net of all derivative financial instruments (current and noncurrent). It does not consider liabilities for lease and acquisition of companies payable. 2. Cash and cash equivalent and Financials Cash and Equivalents Financial Invesments 614 679 654 25 134 (0) (34) (12) (24) 23 (20) 26 (14) (11) 26638 705 680 Cash Jun/25 Reconciliation of Results Δ Working Capital Interest Paid Income Tax Investment (ex- financial app.) Financial Investment Income Financing Cash Sep/25 ex-Buybacks and Exchange Share Buybacks Exchange Costs Cash Sep/25 Net Debt excl. Buybacks and Dividends – R$ Mm 710 771 781 772 738 710 726 725 690 642 45 56 82 96 3Q24 4Q24 1Q25 2Q25 3Q25 Net Debt Net Debt ex Share Buybacks and Dividends Accumulated Share Buybacks and Dividends
Page 12
Leverage Payment Schedule - BRL Million (After Exchange) Average Cost of debt and indexation (Pós Exchange) Transaction costs are not included ✓ The weighted average maturity of Mater Dei's debt is 5.6 years, compared to 3.9 years reported in Q2 2025, an increase explained by the exchange operation that extended the maturity of R$ 700 million in debentures by 4 years. ✓ The average cost of debt in the 3Q25 period was CDI - 0.78% per year, a reduction compared to 2Q25 explained by the 50 bps decrease in the spread on R$ 700 million in debentures through the exchange operation. 55 101 186 1.0154% 7% 14% 75% -100% -80% -60% -40% -20% 0% 20% 40% 60% 80% - 200 400 600 800 1.000 1.200 1.400 1.600 Less than one year Between one and three years Between three and five years More than five years 97% 3% CDI - 0,73% TJLP + 3,18%
Page 13
For questions via audio, please raise your hand to join the line. When announced to ask the question, your microphone will be enabled. We ask for all the questions to be made at once. If you prefer, write your question directly in the Q&A icon ate the bottom of the screen Q&A Imagem Website: ri.materdei.com.br/en E-mail: ri@materdei.com.br